| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb7ce8745175865c6357f7d5fe7fccf5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01a96e8bbea00eeaa0b50c2a0c000dba |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
| filingDate |
2006-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa823e68a9c6b43c1fe99f0cc14cd3c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64de62e9c30009e1371e306c3eceb232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c168634eaa736ba8b90d6c20aa3670cf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b6b1c598263417ef46dd97e4fcaa9d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e9ea1b300a8dfb36dcac9cc7f4edef5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a0e73556d7694b88f2b6b8b59bacbff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a45d3ada8d5fff67f03e89fedb4bcd53 |
| publicationDate |
2010-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-PI0606839-A2 |
| titleOfInvention |
use of a pharmaceutical composition comprising an irreversibly epidermal growth factor receptor (egfr) inhibitor |
| abstract |
USE OF A PHARMACEUTICAL COMPOSITION UNDERSTANDING AN IRREVERSIBLE EPIDERMIC GROWTH FACTOR RECEIVER (EGFR) INHIBITOR. The present invention is directed to methods for the treatment of gefitinib and / or erlotinib resistant cancer. An individual with cancer is monitored for cancer progression following treatment with gefitinib and / or erlotinib. Cancer progression is indicative that the cancer is resistant to gefitinib and / or erlotinib. Once cancer progression is noted, the subject is administered a pharmaceutical composition comprising an irreversible epidermal growth factor receptor (EGFR) inhibitor. In preferred embodiments, the irreversible EGFR inhibitor is EKB-569, HKI-272 and HKI-357. |
| priorityDate |
2005-02-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |